These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29154019)

  • 1. Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals.
    Zhu J; Hazen RJ; Joyce C; Delpino A; Kirkham HS; Strickland CD; Markes-Wilson S; Kim T; Kang M; Rubin RA; Stein LL
    J Am Pharm Assoc (2003); 2018; 58(1):89-93.e2. PubMed ID: 29154019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital.
    Tran AN; Sachdev R; Fricker ZP; Leber M; Zahorian T; Shah B; Nunes DP; Long MT
    Dig Dis Sci; 2018 Dec; 63(12):3241-3249. PubMed ID: 30078116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center.
    Yang S; Britt RB; Hashem MG; Brown JN
    J Manag Care Spec Pharm; 2017 Mar; 23(3):364-369. PubMed ID: 28230455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
    Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
    Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
    Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
    Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a specialty hepatitis C virus telephone pharmacy service.
    Sabourin AA; Fisher-Grant KK; Saulles AR; Mohammad RA
    Am J Health Syst Pharm; 2021 May; 78(Supplement_2):S38-S45. PubMed ID: 33684928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacy programmatic perspectives on use of direct-acting antivirals for acquired hepatitis C infection in solid organ transplant recipients.
    Crona L; Berry H; Byrns J; Campbell U
    Am J Health Syst Pharm; 2020 Jul; 77(14):1149-1152. PubMed ID: 32537658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting.
    Edmonds C; Carver A; DeClercq J; Choi L; Peter M; Schlendorf K; Perri R; Forbes RC; Concepcion BP
    Am J Surg; 2022 May; 223(5):975-982. PubMed ID: 34548142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.
    Krüger K; Krauth C; Rossol S; Mauss S; Boeker KHW; Müller T; Klinker H; Pathil A; Heyne R; Stahmeyer JT;
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):230-240. PubMed ID: 30325794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a specialized pharmacy team.
    Kuwelker S; Tsai E; Kuo L; Kim J; Van Frank T; Mitchell R; Ramirez R; Guerrero R; Hanysak B; Landaverde C; Rodas F; Lawitz E; Basra T; Nguyen H; Christensen K; Vaughn C; Hinojosa K; Olvera N; Caraballo-Gonzalez E; Pham E; Pedicone LD; Poordad F
    Medicine (Baltimore); 2023 Jul; 102(30):e34183. PubMed ID: 37505173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applicability of a new specialty pharmacy-reported measure describing completion of therapy for hepatitis C.
    Bolduc C; McCall K; Stickney K; Gelinas A; Levesque E
    J Manag Care Spec Pharm; 2021 Feb; 27(2):263-267. PubMed ID: 33506724
    [No Abstract]   [Full Text] [Related]  

  • 13. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.
    Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
    Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
    Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
    Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
    HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.
    Norton BL; Fleming J; Bachhuber MA; Steinman M; DeLuca J; Cunningham CO; Johnson N; Laraque F; Litwin AH
    Int J Drug Policy; 2017 Sep; 47():196-201. PubMed ID: 28811158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval.
    Vu TM; Toribio W; Riazi F; Ciprian G; Gibbs N; Giardina M; Camacho JA; Parrella K; Cambe J; Amory C; Chasan R; Sigel KM; Weiss JJ
    J Manag Care Spec Pharm; 2018 Apr; 24(4):329-333. PubMed ID: 29578854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
    Ioannou GN; Feld JJ
    Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy.
    Zaepfel M; Cristofaro L; Trawinski A; McCarthy K; Rightmier E; Khadem T
    Ann Pharmacother; 2017 Apr; 51(4):307-314. PubMed ID: 28228059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.